OFFICIAL PUBLICATION OF

by its subsidiary APPco

Baricitinib update

15/10/2021

New monograph released to guide safe treatment of serious COVID-19 symptoms The Society of Hospital Pharmacists of Australia has brought forward the release of streamlined information on the safe administration of baricitinib for people with severe COVID-19 symptoms requiring ventilation While baricitinib is approved for the treatment of active rheumatoid arthritis and atopic dermatitis, in

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Recent Comments
Popular Posts

Teal questions pharmacist UTI programs

because much of the time, I think they’re giving antibiotics for things that are not UTIsPolitician says "I think" and…

Michael Hewson

Medics to ‘fight’ Doctor of Pharmacy title

Yet right now there are far too many reports from overseas of patients being unsure whether their care is from…

Michael Hewson

In scarce supply

I love a good joke.

Evan Nickols

Concurrent funding for aged care pharmacists and RMMRs needed

I understood that was to happen as a gradual changeover and not an abrupt cessation. Currently we do not have…

Jenny Gowan

Baricitinib update

Previous API acquisition joust not over yet

Next Guild partners for coal industry health

Ceramides: what are they and why are they important?

In the beginning

The signs of ageing

Hyperpigmentation

MENU

Previous API acquisition joust not over yet

Next Guild partners for coal industry health

Related Posts

MENU

Hi there! 👋 Looks like you’re not logged in.